Muscle MRI of classic infantile pompe patients: Fatty substitution and edema‐like changes

ABSTRACT Introduction The aim of this study was to evaluate the muscle MRI pattern of 9 patients (median age: 6.5 ± 2.74 years) affected by classic infantile‐onset Pompe disease who were treated with enzyme replacement therapy. Methods We performed and qualitatively scored T1‐weighted (T1‐w) sequenc...

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 55; no. 6; pp. 841 - 848
Main Authors Pichiecchio, Anna, Rossi, Marta, Cinnante, Claudia, Colafati, Giovanna Stefania, Icco, Roberto, Parini, Rossella, Menni, Francesca, Furlan, Francesca, Burlina, Alberto, Sacchini, Michele, Donati, Maria Alice, Fecarotta, Simona, Casa, Roberto Della, Deodato, Federica, Taurisano, Roberta, Rocco, Maja
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Introduction The aim of this study was to evaluate the muscle MRI pattern of 9 patients (median age: 6.5 ± 2.74 years) affected by classic infantile‐onset Pompe disease who were treated with enzyme replacement therapy. Methods We performed and qualitatively scored T1‐weighted (T1‐w) sequences of the facial, shoulder girdle, paravertebral, and lower limb muscles and short‐tau inversion recovery (STIR) sequences of the lower limbs using the Mercuri and Morrow scales, respectively. Results On T1‐w images, mild (grade 1) or moderate (grade 2) involvement was found in the tongue in 6 of 6 patients and in the adductor magnus muscle in 6 of 9. STIR hyperintensity was detected in all areas examined and was categorized as limited to mild in 5 of 8 patients. Conclusions On T1‐w sequences, mild/moderate adipose substitution in the adductor magnus and tongue muscles was documented. STIR edema‐like alterations of thigh and calf muscles are novel findings. Correlations with biopsy findings and clinical parameters are needed to fully understand these findings. Muscle Nerve 55: 841–848, 2017
Bibliography:None of the other authors have anything to disclose.
Conflicts of Interest
Funding
Dr. Pichiecchio received a speaker fee from Genzyme. Dr. Parini received travel and research grants and honoraria for speaking engagements from Shire, Genzyme, BioMarin, and SOBI. Dr. Fecarotta received travel support for meeting attendance from Actelion Pharmaceuticals Ltd and Genzyme, a Sanofi Company.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.25417